Evidence map›Paper›PMID 31791688›Full record

Trial reportLancet (London, England)2019

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.

Andrew R Clamp, Elizabeth C James, Iain A McNeish, Andrew Dean, Jae-Weon Kim, Dearbhaile M O'Donnell, Jane Hook, Christopher Coyle, Sarah Blagden, James D Brenton and 19 more

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Lancet (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Article
  20. Ovarian cancer.Nature reviews. Disease primers · 2026
    Review

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors.

Andrew R ClampDepartment of Medical Oncology, The Christie National Health Service Foundation Trust, and University of Manchester, Manchester, UK.
Elizabeth C JamesMedical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK. Electronic address: e.james@ucl.ac.uk.
Iain A McNeishDepartment of Surgery and Cancer, Imperial College London, London, UK.
Andrew DeanOncology Department, St John of God Hospital, Subiaco, WA, Australia.
Jae-Weon KimDepartment of Obstetrics and Gynaecology, Seoul National University, Seoul, Korea.
Dearbhaile M O'DonnellCancer Trials Ireland, Dublin, Ireland.
Jane HookSt James' University Hospital, Leeds, UK.
Christopher CoyleQueen Alexandra Hospital, Portsmouth Hospitals National Health Service Trust, Portsmouth, UK.
Sarah BlagdenChurchill Hospital, University of Oxford, Oxford, UK.
James D BrentonLi Ka Shing Centre, Cancer Research UK Cambridge Institute, Cambridge, UK.
Raj NaikGynaecology Oncology Centre, Queen Elizabeth Hospital, Gateshead, UK.
Tim PerrenSt James' University Hospital, Leeds, UK.
Sudha SundarInstitute of Cancer and Genomics, University of Birmingham, Birmingham, UK.
Adrian D CookMedical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK.
Gosala S GopalakrishnanMedical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK.
Hani GabraDepartment of Surgery and Cancer, Imperial College London, London, UK; Early Clinical Development, AstraZeneca, Cambridge, UK.
Rosemary LordDepartment of Oncology, Clatterbridge Cancer Centre, Wirral, UK.
Graham DarkNorthern Centre for Cancer Care, Freeman Hospital, Newcastle, UK.
Helena M EarlDepartment of Medical Oncology, Addenbrooke's Hospital, Cambridge, UK.
Marcia HallDepartment of Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK.
Susana BanerjeeGynaecological Unit, The Royal Marsden National Health Service Foundation Trust and Institute of Cancer Research, London, UK.
Rosalind M GlasspoolBeatson West of Scotland Cancer Centre, Glasgow, UK.
Rachel JonesVelindre Cancer Centre, Wales, UK.
Sarah WilliamsBirmingham City Hospital, Birmingham, UK.
Ann Marie SwartNorwich Medical School, University of East Anglia, Norwich, UK.
Sally StenningMedical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK.
Mahesh ParmarMedical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK.
Richard KaplanMedical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK.
Jonathan A LedermannUniversity College London Cancer Institute, and University College London Hospitals, London, UK.

Funding

Cancer Research UK 12127Cancer Research UK 17092Cancer Research UK 22905Medical Research Council MC_U122861379Medical Research Council MC_UU_12023/20Medical Research Council MC_UU_12023/25Medical Research Council MC_UU_12023/28Medical Research Council MC_UU_12023/9
6 · The paper itself

Abstract

backgroundCarboplatin and paclitaxel administered every 3 weeks is standard-of-care first-line chemotherapy for epithelial ovarian cancer. The Japanese JGOG3016 trial showed a significant improvement in progression-free and overall survival with dose-dense weekly paclitaxel and 3-weekly carboplatin. In this study, we aimed to compare efficacy and safety of two dose-dense weekly regimens to standard 3-weekly chemotherapy in a predominantly European population with epithelial ovarian cancer.

methodsIn this phase 3 trial, women with newly diagnosed International Federation of Gynecology and Obstetrics stage IC-IV epithelial ovarian cancer were randomly assigned to group 1 (carboplatin area under the curve [AUC]5 or AUC6 and 175 mg/m

findingsBetween June 6, 2011, and Nov 28, 2014, 1566 women were randomly assigned to treatment. 72% (365), completed six protocol-defined treatment cycles in group 1, 60% (305) in group 2, and 63% (322) in group 3, although 90% (454), 89% (454), and 85% (437) completed six platinum-based chemotherapy cycles, respectively. Paclitaxel dose intensification was achieved with weekly treatment (median total paclitaxel dose 1010 mg/m

interpretationWeekly dose-dense chemotherapy can be delivered successfully as first-line treatment for epithelial ovarian cancer but does not significantly improve progression-free survival compared with standard 3-weekly chemotherapy in predominantly European populations.

fundingCancer Research UK, Medical Research Council, Health Research Board in Ireland, Irish Cancer Society, Cancer Australia.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsAsian PeopleCarboplatinCarcinomaCarcinoma, Ovarian EpithelialChemotherapy, AdjuvantChemotherapy-Induced Febrile NeutropeniaCytoreduction Surgical ProceduresFallopian Tube NeoplasmsFemaleGynecologic Surgical ProceduresHumansMiddle AgedNeoadjuvant TherapyNeoplasm GradingCarboplatinPaclitaxel

Identifiers

PMID31791688
PMCPMC6902268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.